Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups

[cafead]

via Despite Regeneron’s impressive high-dose Eylea data, its high-stakes launch is delayed thanks to an unexpected FDA rejection.

The FDA turned down the closely-watched eye med because of a manufacturing problems the agency spotted at a third-party drug filler, Regeneron said in a release.

article source